4.01
price down icon1.47%   -0.06
after-market 시간 외 거래: 3.99 -0.02 -0.50%
loading
전일 마감가:
$4.07
열려 있는:
$4.13
하루 거래량:
1.65M
Relative Volume:
1.10
시가총액:
$387.86M
수익:
-
순이익/손실:
$-81.49M
주가수익비율:
-4.9567
EPS:
-0.809
순현금흐름:
$-73.48M
1주 성능:
+2.82%
1개월 성능:
-12.06%
6개월 성능:
+28.53%
1년 성능:
-56.37%
1일 변동 폭
Value
$3.965
$4.20
1주일 범위
Value
$3.76
$4.57
52주 변동 폭
Value
$1.07
$11.46

Rezolute Inc Stock (RZLT) Company Profile

Name
명칭
Rezolute Inc
Name
전화
650-206-4507
Name
주소
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Name
직원
71
Name
트위터
Name
다음 수익 날짜
2026-11-05
Name
최신 SEC 제출 서류
Name
RZLT's Discussions on Twitter

Compare RZLT vs VRTX, MRNA, REGN, ARGX, RVMD

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
RZLT icon
RZLT
Rezolute Inc
4.01 377.22M 0 -81.49M -73.48M -0.809
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
504.73 133.37B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
190.01 79.40B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
735.20 81.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
919.21 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
206.64 43.93B 742.00K -1.37B -1.07B -7.0731

Rezolute Inc Stock (RZLT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-03-25 업그레이드 Wedbush Neutral → Outperform
2025-12-11 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2025-12-11 다운그레이드 Craig Hallum Buy → Hold
2025-12-11 다운그레이드 Wedbush Outperform → Neutral
2024-11-05 개시 Wedbush Outperform
2024-08-27 개시 Guggenheim Buy
2024-07-17 개시 BTIG Research Buy
2024-06-04 개시 Craig Hallum Buy
2024-04-09 개시 Maxim Group Buy
2022-08-02 재개 Canaccord Genuity Buy
2022-06-15 개시 Cantor Fitzgerald Overweight
2021-09-08 개시 ROTH Capital Buy
2021-05-27 개시 Oppenheimer Outperform
2021-05-25 개시 H.C. Wainwright Buy
모두보기

Rezolute Inc 주식(RZLT)의 최신 뉴스

pulisher
Oct 01, 2026

Rezolute Inc. R (6HV1.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 01, 2026
pulisher
Sep 30, 2026

Rezolute Initiated at Buy by Lake Street - Moomoo

Sep 30, 2026
pulisher
Sep 30, 2026

Rezolute Inc (NASDAQ: RZLT) Share Price, RZLT Stock News, RZLT Share Price & Updates - kalkine.ca

Sep 30, 2026
pulisher
Sep 30, 2026

RZLT Initiated Coverage by Lake Street -- Price Target Announced at $9.00 - GuruFocus

Sep 30, 2026
pulisher
Sep 29, 2026

Rezolute stock rating upgraded to Buy at Craig-Hallum on trial data - Investing.com Nigeria

Sep 29, 2026
pulisher
Sep 29, 2026

RZLT Upgraded by Craig-Hallum -- Price Target Raised to $7.00 - GuruFocus

Sep 29, 2026
pulisher
Sep 28, 2026

Rezolute highlights ENDO data on congenital HI outcomes and tumor HI case series - scanx.trade

Sep 28, 2026
pulisher
Sep 28, 2026

H.C. Wainwright raises Rezolute stock price target on trial data - Investing.com

Sep 28, 2026
pulisher
Sep 25, 2026

Rezolute, Inc. (RZLT) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 25, 2026
pulisher
Sep 25, 2026

RZLT Maintained by HC Wainwright & Co. -- Price Target Raised to $10 - GuruFocus

Sep 25, 2026
pulisher
Sep 25, 2026

Rezolute (NASDAQ:RZLT) Given New $10.00 Price Target at HC Wainwright - MarketBeat

Sep 25, 2026
pulisher
Sep 25, 2026

HC Wainwright & Co. maintains Buy rating on Rezolute, $10 price target - TradingView

Sep 25, 2026
pulisher
Sep 25, 2026

Citizens reiterates Rezolute stock rating on tumor trial results due By Investing.com - Investing.com Canada

Sep 25, 2026
pulisher
Sep 25, 2026

Citizens reiterates Rezolute stock rating on tumor trial results due - Investing.com

Sep 25, 2026
pulisher
Sep 24, 2026

Rezolute Inc (RZLT) Faces Valuation Challenges Amid Cash Burn an - GuruFocus

Sep 24, 2026
pulisher
Sep 24, 2026

Rezolute Q4FY26 Results: EPS misses estimate at $(0.20), net loss narrows - scanx.trade

Sep 24, 2026
pulisher
Sep 24, 2026

Rezolute, Inc. FY 2026: Revenue $0 Net loss $77.6M, EPS $(0.75) — 10-K Summary - TradingView

Sep 24, 2026
pulisher
Sep 24, 2026

Rezolute Fiscal Q4 Loss Narrows - marketscreener.com

Sep 24, 2026
pulisher
Sep 24, 2026

Rezolute reports FY2026 net loss $77.6M, cash and investments $107.8M as of June 30, 2026 - TradingView

Sep 24, 2026
pulisher
Sep 24, 2026

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update - The Manila Times

Sep 24, 2026
pulisher
Sep 24, 2026

Rezolute Reports $20.5 Million Fourth-Quarter Loss and $107.8 Million Cash - Quiver Quantitative

Sep 24, 2026
pulisher
Sep 24, 2026

Rezolute Q4 net loss narrows as R&D expenses fall - TradingView

Sep 24, 2026
pulisher
Sep 24, 2026

Press Release: Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update - Moomoo

Sep 24, 2026
pulisher
Sep 21, 2026

Rezolute Inc (RZLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Sep 21, 2026
pulisher
Sep 19, 2026

Should I Buy RZLT? RZLT 2026 AnalysisIntellectia AI™ - Intellectia AI

Sep 19, 2026
pulisher
Sep 17, 2026

Rezolute Inc. (RZLT) Q2 2026 Earnings: Narrower-Than-Expected Loss Offers Modest BeatOne-Time Loss Impact - careplusvn.com

Sep 17, 2026
pulisher
Sep 15, 2026

Rezolute Inc. (NV) (RZLT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Sep 15, 2026
pulisher
Sep 14, 2026

Weekly Recap: Strong retention in sunRIZE extension and buy‑tilt at $6 - TradingView

Sep 14, 2026
pulisher
Sep 11, 2026

Rezolute, Inc. expected to post a loss of 15 cents a shareEarnings Preview - TradingView

Sep 11, 2026
pulisher
Sep 10, 2026

Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset - Seeking Alpha

Sep 10, 2026
pulisher
Sep 10, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Sep 10, 2026
pulisher
Sep 09, 2026

Rezolute (RZLT) FDA Review Highlights Uncertain Path Amid Cash-F - GuruFocus

Sep 09, 2026
pulisher
Sep 09, 2026

Rezolute says late-stage trial data for lead asset remains under FDA review - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com Nigeria

Sep 09, 2026
pulisher
Sep 09, 2026

Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint - Yahoo Finance

Sep 09, 2026
pulisher
Sep 09, 2026

Rezolute (RZLT) Updates FDA Review of Phase 3 Data Amid Unprofitable Status - GuruFocus

Sep 09, 2026
pulisher
Sep 09, 2026

Rezolute awaits FDA feedback on congenital HI treatment data - investing.com

Sep 09, 2026
pulisher
Sep 09, 2026

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism - The Manila Times

Sep 09, 2026
pulisher
Sep 09, 2026

RZLT Q4'26 Earnings: EPS estimate is (0.15) USD - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

FDA is still reviewing Rezolute’s experimental drug. No timeline is set. - Stock Titan

Sep 09, 2026
pulisher
Sep 09, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 09, 2026
pulisher
Sep 04, 2026

Rezolute Stock Price Forecast. Should You Buy RZLT? - StockInvest.us

Sep 04, 2026
pulisher
Sep 03, 2026

Rezolute (RZLT) CCO sells stock to cover RSU taxes - stocktitan.net

Sep 03, 2026
pulisher
Sep 03, 2026

RZLT Q4'26 Earnings: revenue estimate is 0 USD - tradingview.com

Sep 03, 2026
pulisher
Aug 29, 2026

Rezolute (RZLT) Shares Decline 7% as Stock Approaches Key Support at $4.39Diagonal Spread Trade - vinanet.vn

Aug 29, 2026
pulisher
Aug 25, 2026

Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Aug 25, 2026
pulisher
Aug 22, 2026

Rezolute, Inc.'s (NASDAQ:RZLT) Shift From Loss To Profit - Simply Wall Street

Aug 22, 2026
pulisher
Aug 20, 2026

Balyasny Asset Management L.P. Reduces Stake in Rezolute Inc (RZ - GuruFocus

Aug 20, 2026
pulisher
Aug 19, 2026

Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 19, 2026
pulisher
Aug 17, 2026

Rezolute Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 17, 2026
pulisher
Aug 17, 2026

Bank of New York Mellon Corp Sells 481,913 Shares of Rezolute, Inc. $RZLT - MarketBeat

Aug 17, 2026

Rezolute Inc (RZLT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Rezolute Inc 주식 (RZLT) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Hogenhuis Wladimir
Director
Dec 16 '25
Buy
1.69
5,650
9,548
119,675
ROBERTS BRIAN KENNETH
Chief Medical Officer
Dec 16 '25
Buy
1.70
28,000
47,600
308,352
Evans Daron
CFO
Dec 15 '25
Buy
1.77
40,000
70,640
415,900
Evans Daron
CFO
Dec 15 '25
Buy
1.79
5,000
8,938
7,000
Elam Nevan C
CEO
Dec 15 '25
Buy
1.59
32,000
50,880
641,119
Karnawat Sunil Ratilal
Chief Commercial Officer
Dec 15 '25
Buy
1.62
12,100
19,599
71,542
Evans Daron
CFO
Dec 09 '25
Buy
5.04
10,549
53,167
131,900
$96.90
price up icon 0.05%
$57.16
price down icon 0.82%
$35.72
price up icon 0.62%
$219.72
price down icon 4.96%
ONC ONC
$358.07
price down icon 0.20%
$206.64
price up icon 0.36%
자본화:     |  볼륨(24시간):